Avita Medical
1st Floor, Unex House
132-134 Hills Road
Cambridge
CB2 8PA
United Kingdom
Tel: 44-0-1223 341150
Fax: 44-0-1223-341170
Website: http://www.avitamedical.com/
Email: info.eu@avitamedical.com
276 articles about Avita Medical
-
AVITA Medical Reports Third Quarter 2021 Financial Results
5/13/2021
AVITA Medical, Inc. (NASDAQ: RCEL, ASX:AVH) (Company), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today reported financial results for its third quarter of fiscal year 2021, ended March 31, 2021
-
AVITA Medical to Announce Fiscal Third Quarter 2021 Financial Results
4/29/2021
AVITA Medical, Inc., a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced it plans to release its fiscal third quarter 2021 financial results after the market closes on Thursday, May 13, 2021.
-
New RECELL® System Data to be Presented at 43rd Annual John A. Boswick Burn & Wound Care Symposium
4/15/2021
Presentations include data highlighting real-world use of RECELL in combination with complementary treatments, clinical versatility, and cost effectiveness of RECELL to advance patient care
-
15 RECELL® System Abstracts Accepted for Presentation at 53ʳᵈ Annual American Burn Association MeetingRecord Number of Accepted Abstracts Highlight Benefits of RECELL System and Reinforce Rapid Adoption by Surgeons to Advance Burn Care
3/30/2021
AVITA Medical, Inc., a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced that 15 abstracts highlighting the clinical and cost-savings benefits of the RECELL® Autologous Cell Harvesting Device have been accepted at the American Burn Association 53rd Annual Meeting.
-
AVITA Medical, Inc. Names Michael Holder as Chief Financial Officer
3/22/2021
AVITA Medical, Inc. (Nasdaq: RCEL; ASX: AVH) (“AVITA Medical”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the appointment of Michael Holder as Chief Financial Officer effective March 22, 2021.
-
Avita Medical, Inc. Announces Closing of Offering of 3,214,250 Shares of Common Stock
3/1/2021
AVITA Medical, Inc. (Nasdaq: RCEL; ASX: AVH) (“AVITA Medical”), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today announced the successful closing of an underwritten registered public offering of its shares of common stock, the details of which were released to the market on February 24, 2021
-
AVITA Medical, Inc. Announces Pricing of Its Public Offering of Common Stock - Feb 25, 2021
2/25/2021
AVITA Medical, Inc., a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced the pricing of its previously announced underwritten registered public offering of 2,795,000 shares of its common stock at a public offering price of US$21.50 per share.
-
AVITA Medical to Present at Upcoming Investor Conferences
2/18/2021
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that its management will present at the following upcoming investor conferences:
-
AVITA Medical Reports Full Second Quarter 2021 Financial Results
2/11/2021
AVITA Medical, Inc., a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, reported financial results for its second quarter of fiscal year 2021, ended December 31, 2020.
-
AVITA Medical to Present at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference
2/3/2021
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that its management will present at the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 17, 2021
-
AVITA Medical to Announce Fiscal Second Quarter 2021 Financial Results
1/28/2021
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today it plans to release its fiscal second quarter 2021 financial results after the market closes on Thursday, February 11,
-
AVITA Medical Announces Preliminary Fiscal Second Quarter 2021 Results
1/12/2021
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, today announced preliminary unaudited estimates of its top line results for the three months ended December 31, 2020.
-
AVITA Medical to Present at the J.P. Morgan 39th Annual Healthcare Conference
12/28/2020
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that management will present at the J.P. Morgan 39th Annual Healthcare Conference on Thursday, January 14, 2021 at 11:40 a.m. Eastern Time. A live, audio-only webcast of the presentat
-
RECELL® System Data Presented at American Burn Association Fall Regional Burn Conferences
12/15/2020
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the presentation of RECELL® System data recently presented at the Northeast Regional Burn Conference and Southern Regional Burn Conference of the American Burn Association.
-
AVITA Medical Limited Implementation of the Scheme of Arrangement to Redomicile from Australia to the United States of America
6/29/2020
AVITA Medical Limited ACN 058 466 523 is pleased to announce that the scheme of arrangement to effect the redomiciliation of the Company and its subsidiaries from Australia to the United States of America has been implemented.
-
AVITA Medical Limited Proposed Redomiciliation to the United States of America - Results of Scheme Meeting
6/15/2020
AVITA Medical Limited ACN 058 466 523 is pleased to announce that shareholders voted in favour of the scheme of arrangement to effect a redomiciliation of the Company and its subsidiaries from Australia to the United States of America, under which AVITA Therapeutics, Inc., a company incorporated in the State of Delaware in the United States of America, will become the parent company of the Avita Group.
-
AVITA Medical Limited Proposed Redomiciliation to the United States of America - Chair’s Address to Scheme Meeting
6/14/2020
In accordance with ASX Listing Rule 3.13.3, AVITA Medical Limited ACN 058 466 523 is pleased to provide a copy of the Chair’s address for the Scheme Meeting being held virtually at 9.00am, being Monday, 15 June 2020.
-
AVITA Medical Files RECELL® System Investigational Device Exemption (IDE) Application with the U.S. Food and Drug Administration for Treatment of Vitiligo
6/1/2020
AVITA Medical Limited (ASX: AVH) (NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, today announced that it has submitted an Investigational Device Exemption (IDE) supplement with the U.S. Food and Drug Administration (FDA) for the initiation of a pivotal clinical trial to investigate the RECELL® System for the treatment of vitiligo.
-
AVITA Medical to Participate at the Jefferies Virtual Healthcare Conference
5/21/2020
AVITA Medical Limited ( Company ) (ASX:AVH) (NASDAQ:RCEL) today announced that management will present virtually at the upcoming Jefferies Virtual Health Conference on Wednesday, June 3, 2020 at 4:30 p.m. EDT. Authorised for release by the Chief Financial Officer of AVITA Medical Limited. ABOUT AVITA MEDICAL LIMITED AVITA Medical is a regenerative medicine company with a techno
-
AVITA Medical Limited Proposed Redomiciliation to the United States of America – Registration of Scheme Booklet with ASIC and Financial Reporting Relief Granted by ASIC
5/11/2020
AVITA Medical Limited is pleased to announce that the Australian Securities and Investments Commission has registered the scheme booklet in relation to the proposed scheme of arrangement under which AVITA Therapeutics, Inc., a newly-formed company incorporated in Delaware in the United States of America, will become the parent company of the Company and its subsidiaries for the purposes of effecting a redomiciliation of the Avita Group from Australia to the United States of America.